Item 9 Labs Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Item 9 Labs has 701.81 million shares outstanding.
| Current Share Class | 701.81M |
| Shares Outstanding | 701.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | 0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06, with a Debt / Equity ratio of 0.65.
| Current Ratio | 0.06 |
| Quick Ratio | 0.02 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | -13.20 |
| Interest Coverage | -1.09 |
Financial Efficiency
Return on equity (ROE) is -47.36% and return on invested capital (ROIC) is -6.42%.
| Return on Equity (ROE) | -47.36% |
| Return on Assets (ROA) | -5.40% |
| Return on Invested Capital (ROIC) | -6.42% |
| Return on Capital Employed (ROCE) | -18.88% |
| Weighted Average Cost of Capital (WACC) | 21.20% |
| Revenue Per Employee | 194,958 |
| Profits Per Employee | -307,274 |
| Employee Count | 101 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 3.28 |
Taxes
In the past 12 months, Item 9 Labs has paid 11,197 in taxes.
| Income Tax | 11,197 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.15 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 25.80 |
| Average Volume (20 Days) | 5,805 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.28 |
Income Statement
In the last 12 months, Item 9 Labs had revenue of 19.69 million and -31.03 million in losses. Loss per share was -0.32.
| Revenue | 19.69M |
| Gross Profit | 9.80M |
| Operating Income | -10.04M |
| Pretax Income | -31.04M |
| Net Income | -31.03M |
| EBITDA | -8.46M |
| EBIT | -10.04M |
| Loss Per Share | -0.32 |
Balance Sheet
The company has 183,429 in cash and 34.30 million in debt, with a net cash position of -34.11 million or -0.05 per share.
| Cash & Cash Equivalents | 183,429 |
| Total Debt | 34.30M |
| Net Cash | -34.11M |
| Net Cash Per Share | -0.05 |
| Equity (Book Value) | 52.64M |
| Book Value Per Share | 0.51 |
| Working Capital | -55.47M |
Cash Flow
In the last 12 months, operating cash flow was -1.12 million and capital expenditures -1.48 million, giving a free cash flow of -2.60 million.
| Operating Cash Flow | -1.12M |
| Capital Expenditures | -1.48M |
| Free Cash Flow | -2.60M |
| FCF Per Share | -0.00 |
Margins
Gross margin is 49.79%, with operating and profit margins of -51.01% and -157.61%.
| Gross Margin | 49.79% |
| Operating Margin | -51.01% |
| Pretax Margin | -157.65% |
| Profit Margin | -157.61% |
| EBITDA Margin | -42.96% |
| EBIT Margin | -51.01% |
| FCF Margin | n/a |
Dividends & Yields
Item 9 Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.58% |
| Shareholder Yield | -3.58% |
| Earnings Yield | -4,420,888.03% |
| FCF Yield | -369,970.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 18, 2018. It was a reverse split with a ratio of 0.05.
| Last Split Date | Oct 18, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
Item 9 Labs has an Altman Z-Score of -1.41 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.41 |
| Piotroski F-Score | 2 |